UK - Bowmark Capital generates 6.7x return on Medscreen exit

Bowmark Capital has sold its majority interest in drug and alcohol testing services provider Medscreen Holdings Ltd to Concateno Plc, an AIM-listed company. The exit has generated an IRR of 52% and a return of 6.7x for Bowmark Capital.